Equities

Heart Test Laboratories Inc

HSCS:NAQ

Heart Test Laboratories Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.11
  • Today's Change-0.47 / -10.26%
  • Shares traded18.00
  • 1 Year change-95.28%
  • Beta--
Data delayed at least 15 minutes, as of Jul 29 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Company’s initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.

  • Revenue in USD (TTM)18.60k
  • Net income in USD-6.39m
  • Incorporated2007
  • Employees12.00
  • Location
    Heart Test Laboratories Inc550 Reserve St, Suite 360SOUTHLAKE 76092United StatesUSA
  • Phone+1 (682) 237-7781
  • Websitehttps://heartsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hawkeye Systems Inc0.00-804.18k1.95m44.00---------0.1186-0.11860.00-0.290.00-------66.07-330.11-----------218.49---2.7810.45------4.85------
NanoVibronix Inc2.85m-3.20m2.12m10.00--0.6063--0.7454-1.72-1.721.451.260.5160.368313.64285,000.00-57.98-116.16-101.17-169.3668.9850.47-112.35-570.471.38-13.470.00--203.5948.3331.88---34.02--
Avinger Inc7.62m-16.13m2.17m68.00------0.2853-18.16-18.167.49-2.560.40841.206.38112,102.90-102.83-70.93---131.5722.4330.87-251.78-208.910.4764-10.021.38---7.51-0.673632.76---24.21--
Tenon Medical Inc3.21m-14.33m2.18m21.00--6.64--0.6786-7.24-7.241.430.97240.41082.787.25153,047.60-183.10---269.43--54.70---445.77--2.35--0.00--323.73--17.63------
DermTech Inc15.66m-89.63m2.24m206.00--0.056--0.1429-2.69-2.690.46521.140.111911.925.0676,038.84-64.00---71.29--8.51---572.19--3.46--0.0013--5.36--13.54------
Kelyniam Global Inc517.70k-420.28k2.40m0.00--4.47--4.63-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
BIOLASE Inc48.83m-38.26m2.66m157.00------0.0546-20.50-20.508.640.00811.282.219.00311,006.40-55.75-49.28-118.58-85.8034.2535.27-43.56-50.720.6409-5.980.9812--1.451.27-30.39--18.63--
Heart Test Laboratories Inc18.60k-6.39m2.69m12.00--30.28--144.87-0.4912-0.49120.00090.13570.00260.0092.531,550.00-89.51---120.71--67.31---34,362.42--4.70-16.410.0547---64.16---31.61------
Vycor Medical Inc1.44m-425.52k2.87m8.00------2.00-0.0133-0.01350.0425-0.10781.590.66726.81179,572.50-11.22-47.86----89.4889.60-7.04-35.420.0861-0.0247----19.43-0.654246.49---31.77--
Nuwellis Inc8.90m-19.93m3.18m59.00--21.83--0.358-8.30-8.302.730.13040.70761.557.04150,762.70-143.62-98.07-216.07-122.4857.4155.22-202.97-230.510.7092-4.750.00--3.7612.14-55.78--4.61--
Therapeutic Solutions International Inc97.68k-2.18m3.21m3.00--2.10--32.90-0.0006-0.00060.000030.00030.02571.305.4432,560.00-63.47-162.32-172.17--63.3667.79-2,468.37-2,391.850.4652-6.420.2868---52.1395.3543.11------
Invo Bioscience Inc4.25m-7.08m3.28m25.00------0.7714-5.68-5.682.590.00390.34739.5030.72169,953.20-57.87-94.63-128.00-151.4539.9074.91-166.64-343.110.1629-5.860.9965--267.3843.6226.24--87.09--
Fuse Medical Inc18.40m3.63m3.33m31.001.25--0.90160.18070.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Bioelectronics Corp1.61m-289.82k3.46m9.00------2.15-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Data as of Jul 29 2024. Currency figures normalised to Heart Test Laboratories Inc's reporting currency: US Dollar USD

Institutional shareholders

1.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20241.92k0.29%
Tradition Wealth Management LLCas of 31 Mar 20241.81k0.28%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20241.65k0.25%
Citadel Securities LLCas of 31 Mar 20241.23k0.19%
HRT Financial LLCas of 31 Mar 20241.23k0.19%
HCR Wealth Advisorsas of 31 Mar 20241.00k0.15%
First Western Trust Bank /Investment Management/as of 31 Mar 2024750.000.11%
Oliver LaGore VanValin Investment Group, Inc.as of 31 Mar 2024704.000.11%
Tower Research Capital LLCas of 31 Mar 2024625.000.10%
Two Sigma Securities LLCas of 31 Mar 2024505.000.08%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.